Effects of neoadjuvant chemotherapy on the pharmacodynamics of rocuronium bromide in patients undergoing gastric cancer surgery

doi:10.12092/j.issn.1009-2501.2019.10.012

Abstract

Abstract:

AIM: To evaluate the effect of neoadjuvant chemotherapy on neuromuscular block induced by rocuronium in the patients undergoing radical gastrectomy. METHODS:Fifty patients with open gastric cancer, ASA Ⅰ or Ⅱ, aged 40 to 68 years old, 56-79 kg, scheduled for elective radical gastrectomy, were divided into 2 groups (n=25 each) according to whether the patient received neoadjuvant chemotherapy before operation or not: non-chemotherapy group (group N) and neoadjuvent chemotherapy group (group C). Anesthesia was induced with rocuronium 0.9 mg/kg injected intravenous. When T1 recovered to 25% of control height, IV infusion of rocuronium 0.15 mg/kg was used. The onset time, time for T1 to recover to 25%, recovery index and time for train of four ratios to recover to 90%, and the total amount of rocuronium were recorded. RESULTS:Compared with the group N, time for T1 to recover to 25%, recovery index and time for train of four ratios to recover to 90% were significantly prolonged, and the consumption of rocuronium was decreased in group C. There was no significant difference of onset time between the two groups. CONCLUSION:Neoadjuvant chemotherapy can reduce the usage of muscle relaxant in the patients undergoing radical gastrectomy.

Key words: chemotherapy, rocuronium bomide, pharmacodynamics, gastric cancer

CLC Number:

R749

LIAN Yanhong, JIANG Huifang, YUAN Xiaohong, ZHOU Huidan, XIE Kangjie, FANG Jun, JIN Xiaoju. Effects of neoadjuvant chemotherapy on the pharmacodynamics of rocuronium bromide in patients undergoing gastric cancer surgery[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1161-1164.

References

［1］Geisler S, Doan RA, Cheng GC, et al. Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program［J］. JCI Insight, 2019, 4(17): 1-17.
［2］Xue K, Ying X, Bu Z, et al. Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II-III randomized trial ［J］. Chin J Cancer Res, 2018, 30(5): 516-525.
［3］Seretny M, Currie GL, Sena ES,et al. Incidence, prevalence, and predictors of chemotherapy-inducedperipheral neuropathy: a systematic review and meta-analysis［J］. Pain, 2014, 155(12): 2461-2470.
［4］Khuenl KS, Sparr H. Clinical pharmacokinetics of rocuronium bromide ［J］. Clin Pharmacokinet, 1996, 31(3): 174-183.
［5］Fuchs-Buder T, Claudius C, Skovgaard LT, et al. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision ［J］. Acta Aaesthesiol Seand, 2007, 51(7): 789-808.
［6］Hirakawa M, Sato Y, Ohnuma H, et al. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker ［J］. Cancer Chemother Pharmacol, 2013, 71: 789-797.
［7］Inoue K, Nakane Y, Kogire M, et al. Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer［J］. Eur J Surg Oncol, 2012, 38: 143-149.
［8］Mathijssen RH, van Schaik RH. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment ［J］. Eur J Cancer, 2006, 42(2): 141-148.
［9］沈冬，宋宇. 卡培他滨维持化疗治疗晚期胃癌和术后复发转移胃癌的安全性及预后分析［J］. 现代肿瘤医学, 2015, 23(18): 2646-2649.
［10］康定鑫，姬斌，李军. 七氟烷和地氟烷对小儿手术中罗库溴铵持续输注速率的影响［J］. 中国临床药理学杂志，2017，33(21)：2120-2123．
［11］Kim YB，Lee S，Lee KC, et al. Effects of presynaptic muscarinic cholinoreceptor blockade on neuromuscular transmission as assessed by the train-of-four and the tetanic fade response to rocuronium ［J］. Clin Exp Pharmacol Physiol，2017，44(7)：795-802．
［12］Paris I, Cappellini GC, Malaguti P, et al. Pharmacogenomics and chemotherapy［J］. Recenti Prog Med, 2010, 101(7/8): 277-282.
［13］曹冬冬, 王吨卫, 马雯, 等. 新辅助化疗因素对胃癌根治术患者顺阿曲库铵肌松效应的影响［J］. 中华麻醉学杂志, 2017, 37(5): 588-590.
［14］赵婷, 肖春龙. 术前新辅助化疗对乳腺癌根治术患者顺式阿曲库铵肌松效应的影响［J］. 解放军医药杂志, 2018, 30(3): 44-47.
［15］冯趁霞, 刘忠民, 冯桂真, 等. 乳腺癌化疗后对肌松药维库溴铵的影响［J］. 现代医药卫生, 2017, 33(13): 1972-1976.
［16］袁晓红，方军，郭建荣, 等. 急性高容血液稀释对不同剂量罗库溴铵肌松效应的影响［J］. 中国临床药理与治疗学, 2013, 18(12): 1396-1400.
［17］Loupakis F, Masi G, Fornaro L, et al. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma［J］. Cancer Chemother Pharmacol, 2010, 66(3): 559-566.
［18］Swanson HI, Njar VC, Yu Z,et al. Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy［J］. Drug Metab Dispos, 2010, 38(4): 539-544.
［19］Amir PZ, Maziar M, Jalil M, et al. Chemotherapy alters cisatracurium induced neuromuscular blockadecharacteristics: A prospective cohort study ［J］. J Clin Anesth, 2017, 36: 84-87.
［20］Allum WH, Smyth EC, Blazeby JM, et al. Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction［J］. Br J Surg, 2019, 106(9): 1204-1215.

[1]	WANG Ruyue, XIE Fei, WANG Xin, LI Hongyu. Therapeutic effect of lienal polypeptide injection on bone marrow suppression and immunodeficiency in KM mice following chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1000-1007.
[2]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[3]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[4]	WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai. Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
[5]	LI Shuang, HAN Shuzhen, DAI Yuting, XIU Minghui, DU Xianqin, HE Jianzheng, LIN Xingyao. Progress in the prevention and treatment of traditional Chinese medicine based on the mechanism of intestinal injury of various chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 583-593.
[6]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
[7]	GU Yifei, CHU Nannan, HUANG Kai, QUE Linling, ZHANG Jisheng, XIANG Xuemei, HE Qing. Application and progress of pharmacodynamics study in bioequivalence evaluation of orally inhaled drug products [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 822-833.
[8]	ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng. Model informed precision dosing of warfarin: China expert consensus report (2022 version) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212.
[9]	XU Liying, ZHANG Gaosong, HUANG Xiaomin, HUANG Jihan, WANG Shuhua. Clinical efficacy and modeling evaluation of He-wei-zhi-xie capsules in treating diarrhea patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 47-55.
[10]	LIU Le, QI Wenbo, BAI Yuping, LIU Qian, YIN Zhenyu, LI Xiaomei, YU Yang, CHEN Hao. Influencing factors of PD-1/PD-L1 immune checkpoint inhibitor immunotherapy for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 95-101.
[11]	WU Rongrong, CHEN Zhiqiang, JIA Yifei, CHEN Hongqi, WANG Panpan, YAN Ru. Applications of BGUSs inhibition in tumor prevention and chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 964-974.
[12]	JIANG Yuhua, ZHI Hui, LU Linming, TIAN Dahao, WANG Xiaoqing, GE Yu, XIE Shangfu, WANG Qi. AHVAC-I reverses tumor growth of cancer-associated fibroblasats in gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 389-394.
[13]	Pazilaiti YASEN, YUAN Hao, LU Hong, ZHENG Ya, WANG Yuping, ZHOU Yongning. Research progress in clinical trials of targeted drugs for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 454-461.
[14]	ZHAO Quanfeng, FU Peishu, GU Wenrui, ZHEN Dan, LV Zongjie, YANG Yang. Advances in evidence-based medical research of GnRHa for fertility protection after chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1449-1454.
[15]	JIAO Zheng, LI Xingang, SHANG Dewei, DONG Jing, ZUO Xiaocong, CHEN Bing, LIU Jianmin, PAN Yan, ZHOU Tianyan, ZHANG Jing, LIU Dongyang, LI Lujin, FANG Yi, MA Guangli, DING Junjie, ZHAO Wei, CHEN Rui, XIANG Xiaoqiang, WANG Yuzhu, GAO Jianjun, XIE Haitang, HU Pei, ZHENG Qingshan. Model informed precision dosing: China expert consensus report [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1215-1228.